Molecular Pathology of Urological Cancers: Current Advances and Future Perspectives

Dear Colleagues,

In recent decades, the widespread use of PSA has led to overdiagnosis and to an increase in unnecessary biopsies, which has ultimately produced overtreatment of low-risk prostate cancer. For bladder cancer and renal cell carcinoma, there are no specific diagnostic, prognostic, or predictive molecular biomarkers. Testis cancer is generally silenced at its early stage, leading to loss of the opportunity for timely diagnosis and treatment. In this view, both the molecular characterization of the tumor and the identification of molecular biomarkers will provide useful tools for personalized medicine. Many candidate molecules that act as potential biomarkers for clinical management of patients with prostate, bladder, testis, and renal cancers have been proposed, including circulating biomarkers and genes/molecules that are expressed in tumor tissues. Several studies on the potential use of peptides, proteins, nucleic acids, gene expression and mutations, noncoding RNAs and circulating tumor cells are ongoing.

Thus, the content of the Special Issue will focus on current evidence on general approaches which will contribute to further elucidation of the molecular mechanisms underlying urological cancer progression and on advances in preclinical molecular strategies to identify new biomarkers. Original research articles, mini and full reviews, short communications, perspectives, and commentaries are welcome.

On behalf of the Journal of Molecular Pathology, you are warmly invited to contribute an article to the Special Issue “Molecular Pathology in Urological Cancers: Current Advances and Future Perspectives”.

Prof. Dr. Michele Caraglia
Prof. Dr. Daniela Terracciano
Dr. Ashish Chandra
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Molecular Pathology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• prostate cancer
• PSA
• bladder cancer
• renal cancer
• biomarkers
• testis cancer
• endocrine-related cancer
• noncoding RNAs
• metabolomics
• tumor markers
• tumor inflammation
• circulating tumor cells
• circulating free DNA
• tumor mutational status